Tag: Nasdaq

Posted on

GSK Gets Canadian Approval For BREO ELLIPTA For Treatment Of Asthma In Adults – Nasdaq

GSK Gets Canadian Approval For BREO ELLIPTA For Treatment Of Asthma In Adults
Nasdaq
BREO® ELLIPTA is a fixed-dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. Two strengths, 100/25 mcg and 200/25 mcg, have been approved in Canada for use in asthma. BREO is administered …
GSK-Theravance's Breo Ellipta gets Canadian approval to treat asthma in adultsPharmaceutical Business Review
GSK Receives Approval for BREO(R) ELLIPTA(R) for the Treatment of Adults With …MarketWatch

all 7 news articles »

View full post on asthma – Google News

Posted on

Teva’s Asthma Drug ‘Significantly’ Improves Lung Function In Phase 3 Trials – NASDAQ

Teva's Asthma Drug 'Significantly' Improves Lung Function In Phase 3 Trials
NASDAQ
(RTTNews.com) – Teva Pharmaceutical Industries Ltd. ( TEVA ) Monday said asthma patients with elevated eosinophils showed significant improvement in lung function and asthma control after being treated with reslizumab in final-stage studies of the anti …

and more »

View full post on asthma – Google News

Posted on

Glaxo, Theravance File Asthma Drug Application with FDA – NASDAQ

Glaxo, Theravance File Asthma Drug Application with FDA
NASDAQ
LONDON–GlaxoSmithKline PLC (GSK.LN) and Theravance Inc. ( THRX ) have submitted a supplemental new drug application to the U.S. Food and Drug Administration for a drug used for treatment of asthma in patients aged 12 years and older. The British …
GSK and Theravance Announce Submission to US Regulatory Authorities for …MarketWatch
Glaxo And Theravance Submits Supplemental NDA For Breo ElliptaLondon South East

all 3 news articles »

View full post on asthma – Google News

Posted on

Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And … – NASDAQ

Teva Gets Positive CHMP Opinion For DuoResp Spiromax To Treat Asthma And …
NASDAQ
DuoResp Spiromax is a new multi-dose dry-powder inhaler with a combination of budesonide, an inhaled corticosteroid to treat the underlying inflammation in asthma and COPD, and formoterol fumarate dihydrate, a rapid-acting and long-lasting beta2 …
UPDATE 1-EU Agency backs respiratory drugs for approvalReuters
EMA Backs Generic Versions of AstraZeneca's SymbicortBloomberg

all 7 news articles »

View full post on asthma – Google News

Posted on

KaloBios to Stop KB003 Development for Asthma – Analyst Blog – NASDAQ

KaloBios to Stop KB003 Development for Asthma – Analyst Blog
NASDAQ
KaloBios Pharmaceuticals, Inc. ( KBIO ) announced disappointing top line results from a phase II study on KB003 in patients suffering from severe asthma, where the candidate failed to meet the key endpoints. We expect the news to have a significant …
KaloBios shares tank on failed asthma drug trialSan Francisco Business Times (blog)
KaloBios calls it quits on its asthma drug after a Phase II flopFierceBiotech
KaloBios Pharma pulls plug on asthma drug, shares plungeReuters
MarketWatch
all 32 news articles »

View full post on asthma – Google News

Posted on

MediciNova Reports Third Quarter 2012 Results and Update on MN-221 … – NASDAQ

MediciNova Reports Third Quarter 2012 Results and Update on MN-221 …
NASDAQ
The decrease in research and development expenses was mainly due to a decrease in spending on MN-221 due to the completion of the MN-221-CL-007 trial in patients with acute exacerbations of asthma, partially offset by an increase in spending on our …
MediciNova Says Considering Cost, Timing and Design of Future Trials; FDA …Benzinga

all 8 news articles »

View full post on asthma – Google News